Supplementary Table S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S2 summarizes the potency of BBO-8520, sotorasib, adagrasib and RMC-6291 on pERK and viability in a panel of KRAS mutant, wild type and BRAF V600E mutant cell lines
Source: Figshare
Authors: Anna E. Maciag (20814097), James P. Stice (20814100), Bin Wang (20814103), Alok K. Sharma (20814106), Albert H. Chan (20814109), Ken Lin (20814112), Devansh Singh (20814115), Marcin Dyba (20814118), Yue Yang (20814121), Saman Setoodeh (20814124), Brian P. Smith (20814127), Jin Hyun Ju (20814130), Stevan Jeknic (20814133), Dana Rabara (20814136), Zuhui Zhang (20814139), Erik K. Larsen (20814142), Dominic Esposito (15086389), John-Paul Denson (20814145), Michela Ranieri (17079387), Mary Meynardie (20814148), Sadaf Mehdizadeh (20814151), Patrick A. Alexander (20814154), Maria Abreu Blanco (20814157), David M. Turner (20814160), Rui Xu (20814163), Felice C. Lightstone (20814166), Kwok-Kin Wong (15044412), Andrew G. Stephen (17078984), Keshi Wang (20814169), Dhirendra K. Simanshu (15111043), Kerstin W. Sinkevicius (15092407), Dwight V. Nissley (20814172), Eli Wallace (20814175), Frank McCormick (15123867), Pedro J. Beltran (20814178)
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7165058114